Welcome to our dedicated page for America Great SEC filings (Ticker: AAGH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
America Great Health filings document public-company governance and executive-officer changes for the Wyoming registrant. Its Form 8-K disclosures center on Item 5.02 matters, including the departure of a principal financial officer and interim assignment of chief financial officer, principal financial officer, and principal accounting officer responsibilities. The filing record also identifies the company as an Exchange Act reporting issuer and records formal board and signature actions tied to material events.
America Great Health reported quarterly sales of $187,559 for the three months ended September 30, 2025, up from $140,126 a year earlier, but still posted a net loss of $85,363.
Gross profit was $112,679, while operating expenses fell to $116,063, narrowing the loss versus the prior-year period. Cash was only $28,079 with total liabilities of $6,070,405 and a shareholders’ deficit of $5,829,109, leading management to state there is substantial doubt about the company’s ability to continue as a going concern.
The company relies on high-interest short- and long-term loans, including $1,323,138 in long-term debt at rates up to 20%, and advances from its majority shareholder to fund operations.
America Great Health reported modest growth but remains deeply unprofitable and financially stressed for the year ended June 30, 2025. Sales rose to $391,743 from $294,670 and gross profit doubled to $339,121, helped by lower cost of goods sold.
Operating expenses were $722,056, leading to a net loss of $721,242, narrower than the $1,226,362 loss a year earlier. Cash was only $44,056, with a working capital deficit of $3,584,235 and total shareholders’ deficit of $5,743,827, creating substantial doubt about the company’s ability to continue as a going concern.
The auditor issued a disclaimer of opinion on the 2025 and 2024 financial statements due to insufficient audit evidence over expenses, opening balances and the Purecell Group consolidation analysis. The company also reported material weaknesses in internal control, relies heavily on loans and advances from its majority shareholder, and its thinly traded OTC penny stock faces limited liquidity.
America Great Health reported that its Chief Financial Officer, Quinn Chen, submitted his resignation, which the company accepted on June 2, 2025, to be effective June 30, 2025. The company states that Mr. Chen is leaving for personal reasons and that there were no disagreements with the company, including no issues related to its operations, policies, or accounting practices.
The Board plans to search for internal and external candidates to fill the CFO role. Until a successor is appointed, President and Chief Executive Officer Mike Wang will also serve as Chief Financial Officer, acting as the company’s principal financial and principal accounting officer.
America Great Health reported that its Chief Financial Officer, Quinn Chen, submitted his resignation, which the company accepted on June 2, 2025, to be effective June 30, 2025. The company states that Mr. Chen is leaving for personal reasons and that there were no disagreements with the company, including no issues related to its operations, policies, or accounting practices.
The Board plans to search for internal and external candidates to fill the CFO role. Until a successor is appointed, President and Chief Executive Officer Mike Wang will also serve as Chief Financial Officer, acting as the company’s principal financial and principal accounting officer.